Shengbai Oral Liquid (Mixture) was included in the "2018 Clinical Pathway Therapeutic Drug Interpretation: Tumor Disease Volume" anti-tumor Chinese patent medicine

Shengbai Oral Liquid (Mixture) was included in the "2018 Clinical Pathway Therapeutic Drug Interpretation: Tumor Disease Volume" anti-tumor Chinese patent medicine

2018-11-12

PREVOverview of the research on the prevention and treatment of leukopenia after chemoradiotherapy NEXTShengbai Oral Liquid (Mixture) was included in the "2018 Clinical Pathway Therapeutic Drug Interpretation: Blood Diseases Volume" for the treatment of Chinese patent medicines for blood diseases

Hot news

What kind of treatment is needed fo...

How to deal with leukopenia after c...

Should leukopenia be discontinued i...

Should I stop chemotherapy if I h...

Shengbai Oral Liquid (Mixture) w...

Shengbai oral liquid (mixture) was ...

How much do you know about leukopen...

Meta-analysis of the efficacy of S...

Service hotline

0724-8886111

Address：3 Fuyao Yi Lu, Doudao District, Jingmen City, Hubei Province, China
Transmissionh：0724-8686500
Email：hbmy_monyan@163.com

ABOUT

About US Corporate culture Company honor Development course
NEWS

Company dynamics Trade news Academic exchanges
H&R

Job development Talent recruitment
PRODUCTS

Drugs in the field of tumor-re Drugs in other fields Health care products
R&D

R&d pipeline R&d progress Patient recruitment
INVESTOR

Latest announcement

COPYRIGHT© 2022 Hubei Mengyang Pharmaceutical Co., LTD. All Rights Reserved E ICP 11014915; Internet Drug Information Service Certificate No. : (E) - Non-business -2016-0032

Technical Support: SUMA